Patents Represented by Attorney, Agent or Law Firm B. Timothy Creagan
-
Patent number: 6127373Abstract: A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.Type: GrantFiled: September 3, 1998Date of Patent: October 3, 2000Assignee: Pfizer Inc.Inventor: Phillip B. Chappell
-
Patent number: 6110919Abstract: The present invention relates to diazabicyclic compounds and, specifically, to compounds of the formula ##STR1## wherein A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4.sub.1 R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification. The compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.Type: GrantFiled: November 23, 1998Date of Patent: August 29, 2000Assignee: Pfizer Inc.Inventors: Harry R. Howard, Kevin D. Shenk
-
Patent number: 6111105Abstract: The present invention relates to processes for the preparation of 3-(1-piperazinyl)-1,2-benzoisothiazole or its pharmaceutically acceptable salt and to novel intermediates used in the process.Type: GrantFiled: October 15, 1998Date of Patent: August 29, 2000Assignee: Pfizer, Inc.Inventors: Darrell E. Fox, John F. Lambert, Terry G. Sinay, Stanley W. Walinsky
-
Patent number: 6103738Abstract: The invention provides compounds of formula (I), ##STR1## wherein R.sup.1 represents C.sub.1-4 alkoxy optionally substituted by one or more fluorine atoms; R.sup.2 represents H or C.sub.1-6 alkoxy optionally substituted by one or more fluorine atoms; R.sup.3 represents one or more groups independently selected from H, halogen, C.sub.1-4 alkoxy and CF.sub.3 ; in addition, R.sup.2 and one R.sup.3 group may together represent --OCH.sub.2 --, the methylene group being attached to the ortho-position of the pendant phenyl ring; R.sup.4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 17, 1998Date of Patent: August 15, 2000Assignee: Pfizer Inc.Inventors: Alan John Collis, David Nathan Abraham Fox, Julie Newman
-
Patent number: 5968944Abstract: The compounds of the formula wherein A, R.sub.1, R.sub.3, X.sub.1, Y and Z are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.Type: GrantFiled: December 3, 1996Date of Patent: October 19, 1999Assignee: Pfizer Inc.Inventors: Gene M Bright, Willard M Welch, Jr.
-
Patent number: 5958948Abstract: The compounds of the formula wherein A, R.sub.1, R.sub.3, X.sub.1, Y and Z are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.Type: GrantFiled: September 19, 1997Date of Patent: September 28, 1999Assignee: Pfizer, Inc.Inventors: Gene M. Bright, Willard M. Welch, Jr.
-
Patent number: 5935960Abstract: The present invention relates to a pro-drug of ziprasidone or pharmaceutically acceptable salts thereof, processes for its preparation, and pharmaceutical compositions and methods of treatment comprising said pro-drug.Type: GrantFiled: February 7, 1997Date of Patent: August 10, 1999Assignee: Pfizer Inc.Inventors: Stanley W. Walinsky, John F. Lambert
-
Patent number: 5854232Abstract: This invention relates to compounds of formula (IA), (IB), (IC) or (ID), wherein m, X, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.14 and the dotted lines are as defined below, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of using them to treat Alzheimer's disease, age-associated memory impairment, Parkinson's disease and other central nervous system disorders. The claimed compounds have the ability to enhance the release of neurotransmitters such as acetylcholine, dopamine and serotonin.Type: GrantFiled: February 19, 1997Date of Patent: December 29, 1998Assignee: Pfizer Inc.Inventors: Robert A. Volkmann, Vytautas J Jasys, Gene M Bright, Anabella Villalobos, Patricia A Seymour
-
Patent number: 5854239Abstract: The present invention relates to diazabicyclic compounds and, specifically, to compounds of the formula ##STR1## wherein A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification. The compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.Type: GrantFiled: June 20, 1996Date of Patent: December 29, 1998Assignee: Pfizer Inc.Inventors: Harry R. Howard, Kevin D. Shenk
-
Patent number: 5852040Abstract: The present invention is directed to compounds of formula (I), and the pharmaceutically acceptable acid addition salts thereof, wherein R is selected from the group consisting of F,--CF.sub.3, --OCH.sub.3, --O(C.sub.1)alkyl substituted with 1 to 3 fluoro atoms. --O(C.sub.2) substituted with 1 to 5 fluoro atoms, and --O(C.sub.3)alkyl substituted with 1 to 7 fluoro atoms. The compounds of formula (I) are useful in the treatment of stroke, traumatic brain injury and central nervous system degenerative diseases.Type: GrantFiled: April 25, 1995Date of Patent: December 22, 1998Assignee: Pfizer Inc.Inventor: Bertrand Leo Chenard
-
Patent number: 5846965Abstract: Compounds of the formula: ##STR1## wherein: X is O, NH or NR.sup.1 ; R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl or aryl (C.sub.1 -C.sub.4)alkyl; wherein the C.sub.1 -C.sub.6 alkyl group is optionally substituted by fluorine and the C.sub.3 -C.sub.7 cycloalkyl or C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4 )alkyl group is optionally substituted in the cycloalkyl ring by up to two substituents each independently selected from halo, C.sub.1 -C.sub.4 alkoxy or halo(C.sub.1 -C.sub.4)alkoxy; R.sup.2 is phenyl optionally substituted with one or two halo substituents, indolyl or thienyl; R.sup.3 is NH.sub.2, --NR.sup.4 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --NR.sup.4 SO.sub.2 aryl, --NR.sup.4 CO(C.sub.1 -C.sub.6 alkyl), --NR.sup.4 CO aryl or a 5 to 7-membered N-linked cyclic group incorporating W in the ring wherein W is O, NR.sup.5, CH(OH), CHCO.sub.2 H, CHN(R.sup.4).sub.2, CHF, CF.sub.2, C.dbd.O or CH.sub.2 ; R.sup.4 is H or C.sub.1 -C.sub.Type: GrantFiled: January 24, 1997Date of Patent: December 8, 1998Assignee: Pfizer Inc.Inventors: Alexander Roderick MacKenzie, Allan Patrick Marchington, Sandra Dora Meadows, Donald Stuart Middleton
-
Patent number: 5837711Abstract: Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl;X is --CONR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CH.sub.2 OR.sup.3, --CH.sub.2 NR.sup.3 R.sup.4 or --CONR.sup.3 OR.sup.4 ;R.sup.1, R.sup.3 and R.sup.4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms;R.sup.Type: GrantFiled: April 28, 1995Date of Patent: November 17, 1998Assignee: Pfizer Inc.Inventors: Fumitaka Ito, Toshihide Kokura, Masami Nakane, Kunio Satake, Hiroaki Wakabayashi
-
Patent number: 5789423Abstract: This invention provides a compound of the formula: ##STR1## and its pharmaceutically acceptable salts, wherein R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo C.sub.1 -C.sub.6 alkyl or terahydropyranyl, having one or more substituents selected from cyano, 1,3-thiazolanyl, COOR.sup.2, COR.sup.2, OCOR.sup.2, CONR.sup.3 R.sup.4, NR.sup.3 R.sup.4, NR.sup.5 COR.sup.3 and C.ident.CR.sup.6, wherein R.sup.2 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sup.3 and R.sup.4 are independently hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl, R.sup.5 is C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl and R.sup.6 is hydrogen, halo, cyano, C.sub.1 -C.sub.6 alkyl, COOH, COO(C.sub.1 -C.sub.4 alkyl) or phenyl; X is C.sub.1 -C.sub.6 alkoxy or halo C.sub.1 -C.sub.6 alkoxy; and Ar is phenyl optionally substituted with halo.Type: GrantFiled: December 17, 1996Date of Patent: August 4, 1998Assignee: Pfizer Inc.Inventors: Hiroaki Wakabayashi, Yuji Shishido
-
Patent number: 5750535Abstract: The present invention relates to a method treating or preventing disorders caused by a spiral urease-positive gram-negative bacterium such as Helicobacter pylori in mammals, including humans, using compounds that are substance P receptor antagonists and, specifically, using certain quinuclidine derivatives, piperidine derivatives, pyrrolidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds.Type: GrantFiled: August 29, 1995Date of Patent: May 12, 1998Assignee: Pfizer Inc.Inventor: Joanna Clancy
-
Patent number: 5741797Abstract: Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of the formula I and the pharmaceutically-acceptable salts thereof; ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl; X is C.sub.1 -C.sub.6 alkyl having one or more substituents which include at least one heteroatom; Ar.sup.1 and Ar.sup.2 are each, independently, aryl optionally substituted by one C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, halogen, cyano, nitro, phenoxy, mono C.sub.1 -C.sub.6 alkylamino, di C.sub.1 -C.sub.6 alkylamino, halosubstituted C.sub.1 -C.sub.6 alkyl, or halosubstituted C.sub.1 -C.sub.6 alkoxy; Y is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, Z--(CH.sub.2).sub.p --, or W--(CH.sub.2).sub.m --CHR.sup.2 --(CH.sub.2).sub.n --NR.sup.1 CO-- wherein Y is at the 4-, 5- or 6-position on the quinuclidine ring; R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, benzyl or --(CH.sub.2).sub.r --W; R.sup.Type: GrantFiled: November 20, 1995Date of Patent: April 21, 1998Assignee: PFizer Inc.Inventor: Kunio Satake
-
Patent number: 5721255Abstract: The present invention relates to novel substituted benzylamino nitrogen containing non-aromatic heterocycles and, specifically, to compounds of the formula ##STR1## wherein W, R.sup.1, R.sup.2, R.sup.3 and A are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.Type: GrantFiled: February 15, 1995Date of Patent: February 24, 1998Assignee: Pfizer Inc.Inventors: Harry R. Howard, Masami Nakane, Masaya Ikunaka, Kunio Satake, Terry J. Rosen, John A. Lowe, III, Brian T. O'Neill, Fumitaka Ito
-
Patent number: 5705646Abstract: The compounds of the formula ##STR1## wherein A, R.sub.1, R.sub.3, Z and Y are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.Type: GrantFiled: June 14, 1995Date of Patent: January 6, 1998Assignee: Pfizer Inc.Inventors: Gene M. Bright, Willard M. Welch, Jr.
-
Patent number: 5688804Abstract: The present invention relates to the derivatives of the compound of formula (I), which are useful in the treatment of inflammatory and central nervous system disorders, as well as other diorders ##STR1##Type: GrantFiled: January 31, 1995Date of Patent: November 18, 1997Assignee: Pfizer Inc.Inventor: Terry J. Rosen
-
Patent number: 5688809Abstract: The present invention relates to compounds of the formula ##STR1## The present invention also relates to intermediates for the preparation of compounds of the formula I, pharmaceutical compositions and method of use.Type: GrantFiled: October 7, 1996Date of Patent: November 18, 1997Assignee: Pfizer Inc.Inventor: John E. Macor
-
Patent number: 5674732Abstract: The present invention provides a novel culture which belongs to Actinoplanes (Actinoplanes sp. FERM BP-3832). This culture is capable of producing rapamycin more than ten times efficiently than the cultures which have been reported (e.g., Streptomyces hygroscopicus ATCC 29253). The present invention provides a process for the production of rapamycin which comprises cultivating Actinoplanes sp. FERM BP-3832 and thereafter isolating rapamycin from the fermentation mixture.Type: GrantFiled: October 26, 1994Date of Patent: October 7, 1997Assignee: Pfizer Inc.Inventors: Hiroyuki Nishida, Tatsuo Sakakibara, Yuji Yamauchi, Taisuke Inagaki, Yasuhiro Kojima, Nakao Kojima